Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuNano polymeric carrier fabrication technologies for advanced antitumor therapyExpression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic MiceRational combinations of immunotherapeutics that target discrete pathways.Monoclonal TCR-redirected tumor cell killing.Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cellsGenetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsCuring mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumorsImpact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapyPolyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyNew Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesIL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Spleen cells from young but not old immunized mice eradicate large established cancers.How to improve the immunogenicity of chemotherapy and radiotherapy.Is antigen specificity the key to efficient adoptive T-cell therapy?Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Therapeutic cancer vaccines: a long and winding road to success.Oncolytic viruses: a new class of immunotherapy drugs.Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.Dendritic Cells and Cancer Immunity.MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinityRethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer.A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.Optimizing the immune system to achieve control of the metastatic malignant lesion.TNF-α-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma.Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cellsEradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.Immunology: Cross-dressers turn on T cells.Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes.The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
P2860
Q21131200-0F50C9D3-83A4-4EA3-9AF3-CF0B82681484Q28393168-51EF5776-3303-4BA0-9EC8-F937B5BBB1B0Q30399332-A2179156-6A49-4288-9935-71E276EA246DQ33606144-4FFD1BB8-CA41-4E5C-B150-69DCA9C57ACCQ34273053-30149F6B-B526-459B-AE18-7930E597F831Q34370215-05A0ACCB-C1B4-45FB-92F9-586EABBEA7C4Q35001971-E47D0BA0-2726-46A5-88EB-234BAA881BBFQ35024484-63DB5D61-258E-4813-ADC7-A7E08ABFA57CQ35071850-0116B739-7241-4885-BFAF-E5A325D92C66Q35107009-228F36C1-AD3E-4857-AE99-B0C75D61B338Q35570260-E0A2BF07-40B5-46FB-A82B-7C6B7E82F2E0Q36173500-CA9FE3A2-E53B-46EA-89C6-1E8A6CA16DDBQ36249440-B7513FBE-3516-4F71-A8D3-B16D43F83C32Q36349514-B7DDD2D1-A8FA-44D6-B8FC-6C07F52DF370Q36558375-5F061375-D184-468E-A8A9-51CB1EBFCEB9Q37078985-6C0F750A-C681-40F2-A415-3AEE8F165826Q37706396-B8CE7745-01A5-4C91-B26D-B0E3DEE50AAEQ37836489-E58871D0-212B-41EB-8A47-340DBD75BBDDQ37861214-DEDD0C82-0A6B-4DE6-BCE0-B5A765612D72Q37991701-29718C72-2C63-4799-AFDE-675566260C31Q38060734-4C5D00B6-9161-4A3F-946C-74D62B9CAEE8Q38162261-402B7879-8F81-4744-8368-B384AFAB4304Q38577450-F81F815C-FAC1-4FD4-8F36-6D915811DBA4Q38700706-594FB694-D574-4C0A-AFEB-46522C209BFDQ38994017-51A5EEC7-6F26-4B7C-9FC4-B147BEC2D11BQ39290133-1E35C336-FDBE-4ADA-AFEE-2305DEA61AE2Q39414393-14C6FDCD-7EBC-4282-AF93-A989F2EEBB21Q40877959-950F795E-F396-4FC5-AF7D-788B1E3005E5Q40887427-AAD5F54C-3D2B-47EB-8D1B-5173C6CD87ABQ41891271-2C97EB31-97C9-48F8-AA26-2EFF5BF72AD0Q42008502-81FECC4F-440B-40C0-B643-23FCB240D84EQ42028897-C8B0122A-43DA-44FB-9B8A-593137D55728Q42362935-B63724C6-DC3A-4F6F-B639-C0F37DA330DEQ42573824-891B0D4C-367B-45D0-BA7B-7856D714A71EQ43227647-D38B691D-27CB-435A-B99F-908CC8DF1798Q46604950-EB94AFF0-BA40-4CDD-BA35-B83D6149C0AAQ47794460-BCB59EEB-C144-4976-9299-09554747E514Q47809269-7A7A6EB3-7E48-48EE-8649-94EFDD6A9FB9Q48120406-E7F8D822-68EF-411E-B5FC-C04CDEDF3FC3Q48185876-51561758-A1E6-4B5D-A276-8E80854C0FD0
P2860
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bystander killing of cancer requires the cooperation of CD4
@nl
Bystander killing of cancer re ...... lls during the effector phase.
@ast
Bystander killing of cancer re ...... lls during the effector phase.
@en
type
label
Bystander killing of cancer requires the cooperation of CD4
@nl
Bystander killing of cancer re ...... lls during the effector phase.
@ast
Bystander killing of cancer re ...... lls during the effector phase.
@en
prefLabel
Bystander killing of cancer requires the cooperation of CD4
@nl
Bystander killing of cancer re ...... lls during the effector phase.
@ast
Bystander killing of cancer re ...... lls during the effector phase.
@en
P2093
P2860
P356
P1476
Bystander killing of cancer re ...... lls during the effector phase.
@en
P2093
Andrea Schietinger
Hans Schreiber
Karin Schreiber
Mary Philip
Rebecca B Liu
P2860
P304
P356
10.1084/JEM.20092450
P407
P577
2010-10-04T00:00:00Z